Personalized Medicine Fueling Growth In The Biologics Market Is Supporting Development Across The Biologics Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Biologics Market In 2026 And How Much Will It Reach By 2030?

The biologics market has experienced significant expansion in recent years. It is projected to increase from $495.56 billion in 2025 to $540.46 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.1%. Historically, this expansion can be ascribed to several factors, including limited biologics availability, a reliance on conventional therapies, the escalating prevalence of immune-related disorders, improvements in healthcare infrastructure, and increasing physician awareness leading to more prescriptions.

The biologics market is projected to experience substantial expansion in the coming years. It is anticipated to reach $827.24 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. This anticipated growth during the forecast period is fueled by several factors, including the creation of innovative monoclonal antibodies, the broader use of mRNA and viral vector vaccines, the rising uptake of tailored biologic treatments, increasing government backing and financial support for biologics, and the incorporation of digital health and patient surveillance systems. Key developments expected within this period encompass the growing acceptance of monoclonal antibodies and therapeutic proteins, an increase in vaccine development, particularly mRNA and viral vector vaccines, the wider availability of prescription-based biologics and their distribution through hospital pharmacies, an intensified focus on customized medicine and specific biologic therapies, and the integration of biologics with advanced healthcare solutions and patient tracking.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3606&type=smp

Which Significant Factors Are Encouraging Growth In The Biologics Market?

The heightened requirement for personalized medicine is fueling substantial expansion within the worldwide biologics market. This medical methodology, also referred to as precision medicine, involves customizing healthcare and treatments according to each patient’s unique attributes. Personalized medicine facilitates the customization of biological therapies to align with a patient’s distinct genetic and clinical profile, thereby revolutionizing the healthcare sector. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA sanctioned 16 novel personalized treatments for individuals with rare diseases, an increase from six in 2022. Consequently, the rising need for personalized medicine is propelling the future growth of the biologics market.

How Is Segment Classification Applied In The Biologics Market?

The biologics market covered in this report is segmented –

1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines

2) By Drug Classification: Branded Drugs, Generic Drugs

3) By Route Of Administration: Oral, Other Route Of Administration

4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels

Subsegments:

1) By Monoclonal Antibodies (MAbs): Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Therapeutic Proteins: Hormones, Enzymes, Cytokines, Fusion Proteins

3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines

What Trends Are Influencing The Biologics Market?

Leading companies active in the biologics market are prioritizing the development of innovative products, such as biosimilars, to offer economical alternatives to existing biologic therapies. Biosimilars are biologic products that bear a strong resemblance to an already approved reference biologic, exhibiting no significant differences in terms of safety, effectiveness, or quality, which helps in lowering treatment expenses and expanding patient access to advanced medical treatments. For example, in July 2025, Biocon Biologics, a subsidiary of Biocon Limited, an India-based biopharmaceutical firm, introduced Nepexto in Australia, a biosimilar to Enbrel (etanercept). Nepexto is a fusion-protein biologic specifically designed to inhibit tumor necrosis factor-alpha (TNF-a), a primary inflammatory mediator found in autoimmune conditions. It is comprised of a recombinant DNA-derived protein that mimics the binding activity of the original etanercept molecule, thereby delivering comparable efficacy and safety while improving treatment accessibility. Its notable characteristics include high biosimilarity substantiated by strong clinical data, regulatory endorsements, and a reliable supply chain facilitated by its local partner Generic Health, making it a compelling choice for the long-term management of illnesses such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

Who Are The Key Market Participants In The Biologics Market?

Major companies operating in the biologics market are Merck & Co. Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Apotex, Gilead Sciences

Access The Complete Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Which Area Represents The Largest Portion Of The Biologics Market?

North America was the largest region in the biologics market in 2025. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biologics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3606&type=smp

Browse Through More Reports Similar to the Global Biologics Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Orthobiologics Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-devices-and-equipment-global-market-report

Oral Biologics And Biosimilar Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795